<DOC>
	<DOCNO>NCT01954147</DOCNO>
	<brief_summary>Umbilical cord mesenchymal stem cell ( SC ) transplantation novel therapy diabetes mellitus , less side effect advantage . Clinical trial verify good metabolic control would achieve Liraglutide ( GLP-1 ) add conventional therapy . The investigator hypothesize combined therapy umbilical cord mesenchymal stem cell transplantation Liraglutide type 2 diabetes mellitus aid differentiation stem cell insulin-producing cell , improve survival differentiated cell , protect residual beta-cells improve insulin secreting function , achieve favorable glucose homeostasis .</brief_summary>
	<brief_title>Umbilical Cord Mesenchymal Stem Cells Liraglutide Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Male female patient age 35 65 year age . Ability provide write informed consent . Mentally stable able comply procedure study protocol . Clinical history compatible type 2 diabetes ( T2DM ) define ADA ( 1997 ) Diagnosis classification Diabetes Mellitus Basal Cpeptide 0.52.0 ng/mL HbA1c ≥ 7.5 ≤ 11 % standard medical therapy ( SMT ) . Patients must treat SMT 14 month prior match . Insulin dose metformin dos stable 1 month prior match . HbA1c ≥ 7.5 ≤ 10 % time match . Total insulin daily dose ( TDD ) time match exceed 1.0 units/day/kg 18.5 kg/㎡≤BMI≤40.0kg/㎡ Abnormal liver function &gt; 2.5 x ULN Evidence renal dysfunction : serum creatinine &gt; 1.5 mg/dl ( male ) 1.3 mg/dl ( female ) . Gastrointestinal operation history . Type 1 Diabetes mellitus ; DKA ; secondary diabetes . Uncontrolled blood Pressure : SBP &gt; 180 mmHg DBP &gt; 100 mmHg time match . Evidence cardiovascular disease , exist congestive cardiac failure physical exam and/or acute coronary syndrome past 6 month . Presence active proliferative diabetic retinopathy macular edema . Any acute chronic infectious condition criterion investigator would risk patient . For female participant : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study . For male participant : intent procreate 3 month intervention unwillingness use effective measure contraception . Oral contraceptive , Norplant ? , DepoProvera ? , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . Active infection include hepatitis C , HIV , TB determine positive skin test clinical presentation , treatment suspect TB . Subjects treated medication could interfere outcome study : Thiazolidinediones glucagon like peptide 1 ( GLP1 ) analogue ( Exenatide , Byetta ) , Pramlintide ( Amylin ) , Dipeptidylpeptidase IV ( DPPIV ) inhibitor ( i.e . Sitagliptin , Januvia ) Any know suspect allergy liraglutide relevant product . Evidence thyroid adverse event ( serum calcitonin increase , goiter , thyroid cancer , et al ) pancreatitis cause GLP1 analogue . Subjects past history family history Medullary Thyroid Carcinoma ( MTC ) Multiple Endocrine Neoplasia Syndrome Type 2 ( MEN2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>